Compare Novartis AG (NVS) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs VanEck Semiconductor ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while VanEck Semiconductor ETF trades at $583.14. The key difference: Novartis AG pays a 3.17% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals.
| NVS | SMH | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | — |
52-Week High | $168.62 | $668.91 |
52-Week Low | $113.50 | $283.95 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SMH trades at $584.08, up 5.08% today amid volatile semiconductor sector conditions. The ETF shows bearish technical signals with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent institutional buying by firms like Empirical Wealth Management and Assetmark Inc. contrasts with mixed news flow including China's potential AI chip export controls and concerns about AI trade rotation. The fund remains concentrated in top semiconductor names with strong AI exposure.
Outlook remains cautious as semiconductor stocks face sector rotation pressures despite strong AI demand fundamentals. Key risks include geopolitical tensions, potential capex slowdowns, and valuation concerns after the 2026 rally. The current technical setup suggests near-term consolidation between support at $538-$553 and resistance at $569-$584 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
